A single-institution retrospective exploratory analysis on the effectiveness and safety of lenvatinib plus pembrolizumab for advanced endometrial cancer: insights from ProMisE molecular classification system.

Yohei ChibaMasahiro KagabuMitsumasa OsakabeRikako ItoSho SatoEriko TakatoriYoshitaka KaidoTakayuki NagasawaTadahiro ShojiNaoki YanagawaTsukasa Baba

Published in: Japanese journal of clinical oncology (2024)

The p53abn group in the Proactive Molecular Risk Classifier for Endometrial Cancer classification has a poor prognosis even after treatment with lenvatinib/pembrolizumab.

Keyphrases

endometrial cancer
poor prognosis
long non coding rna
advanced non small cell lung cancer
machine learning
single molecule
big data
epidermal growth factor receptor
breast cancer risk